GLPOneReview — News & Updates https://glponereview.com/ Editorial news on GLP-1 telehealth, FDA actions, state pharmacy board decisions, clinical trial readouts, and pricing changes. en-us Wed, 20 May 2026 19:04:18 GMT Foundayo (orforglipron) phase 3 CV safety clears; Q4 launch confirmed https://glponereview.com/news.html#may-14-2026 glponereview-news-2026-05-14 Thu, 14 May 2026 00:00:00 GMT Eli Lilly's phase 3 cardiovascular safety analysis for orforglipron completes; Foundayo on track for Q4 2026 commercial launch. State pharmacy boards open investigations into mass-market compounded GLP-1 https://glponereview.com/news.html#may-8-2026 glponereview-news-2026-05-08 Thu, 08 May 2026 00:00:00 GMT Florida, Texas, and California open formal investigations into 503A vs 503B classification at high-volume telehealth-supplied pharmacies. FDA 503B enforcement period for compounded semaglutide and tirzepatide fully in effect https://glponereview.com/news.html#may-3-2026 glponereview-news-2026-05-03 Sat, 03 May 2026 00:00:00 GMT Transition period following shortage resolutions ends; 503B bulk production of compounded sema/tirz no longer permitted. CMS expands Medicare Part D coverage of Wegovy under SELECT-aligned pathway https://glponereview.com/news.html#april-28-2026 glponereview-news-2026-04-28 Mon, 28 Apr 2026 00:00:00 GMT First material Part D coverage expansion for a weight-management GLP-1 since 2003; covers adults with BMI ≥27 and established CVD.